Pipeline Watch: Phase III Readouts In Cervical Cancer, COVID-19
BeiGene's PARP inhibitor approved in China
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
